You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: Leukogene Therapeutics Inc. Topic: 102
Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: MODULATION THERAPEUTICS, INC. Topic: 102
Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Amelia Technologies LLC Topic: NIEHS
Project SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viabilitySTTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health